Clare Murray, PhD

Clare joined EnPlusOne in 2025 as CEO, bringing significant experience as a company builder, deal maker, and drug developer in the biotechnology industry.

Clare was previously a co-founder of Life Edit Therapeutics, a subsidiary of ElevateBio, where she was a member of the executive leadership team and most recently served as Senior Vice President for Corporate Development and Operations. At Life Edit, Clare led the company through several important milestones including developing and closing transformational deals with Moderna and Novo Nordisk, and advancing programs from indication selection through development candidate nomination. Prior to joining Life Edit, Clare worked at Evotec, SCYNEXIS and Novartis.

Clare Holds an MBA from The Fuqua School of Business, Duke University, a PhD in synthetic organic chemistry from the University of Liverpool, and a BSc in Chemistry from the University of Liverpool.